A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer
Kazmi, Farasat, Nicum, Shibani, Roux, Rene L, Spiers, Laura, Gnanaranjan, Chat, Sukumaran, Ajithkumar, Gabra, Hani, Ghazaly, Essam, McCracken, Nigel W, Harrison, David J, Blagden, Sarah P
Published in Clinical cancer research (01.06.2021)
Published in Clinical cancer research (01.06.2021)
Get full text
Journal Article
The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue
Mutch, Elaine, Nave, Ruediger, McCracken, Nigel, Zech, Karl, Williams, Faith M.
Published in Biochemical pharmacology (15.05.2007)
Published in Biochemical pharmacology (15.05.2007)
Get full text
Journal Article
598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)
Gausdal, Gro, Micklem, David R, Blø, Magnus, Rayford, Austin, Alzhanova, Dina, Madeleine, Noëlly, Taverna, Josephine Amalia, Hung, Chia-Nung, Brekken, Rolf A, Chisamore, Michael, Gorcea-Carson, Claudia, Oliva, Cristina, McCracken, Nigel
Published in Journal for immunotherapy of cancer (01.11.2023)
Published in Journal for immunotherapy of cancer (01.11.2023)
Get full text
Journal Article
Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549)
Nonaka, Takashi, Nave, Rüdiger, McCracken, Nigel, Kawashimo, Atsuko, Katsuura, Yasuhiro
Published in BMC pharmacology (27.09.2007)
Published in BMC pharmacology (27.09.2007)
Get full text
Journal Article
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation
Veluswamy, Rajwanth, Bhalla, Sheena, Mehra, Ranee, Garassino, Marina Chiara, Gligich, Oleg, Oliva, Cristina, Gorcea-Carson, Claudia, McCracken, Nigel William
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC
Bhalla, Sheena, Fattah, Farjana J., Williams, Jessica N., Macchiaroli, Alyssa, Padro, Jonathan, Pogue, Meredith, Dowell, Jonathan, Brekken, Rolf A., Putnam, William C., McCracken, Nigel William, Micklem, David, D'Costa, Zenobia, Gerber, David E.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results
Loges, Sonja, Heuser, Michael, Chromik, Jolanta, Sutamtewagul, Grerk, Kapp-Schwoerer, Silke, Crugnola, Monica, Di Renzo, Nicola, Lemoli, Roberto Massimo, Mattei, Daniele Giovanni, Ben Batalla, Isabel, Waizenegger, Jonas, Janning, Melanie, Rieckmann, Lisa-Marie, Imbusch, Charles, Beumer, Niklas, Micklam, David, Gorcea-Carson, Claudia, Oliva, Cristina, Fiedler, Walter, Alvarado-Valero, Yesid, McCracken, Nigel, Gjertsen, Bjorn T.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
Bhalla, Sheena, Fattah, Farjana J., Ahn, Chul, Williams, Jessica, Macchiaroli, Alyssa, Padro, Jonathan, Pogue, Meredith, Dowell, Jonathan E., Putnam, William C., McCracken, Nigel, Micklem, David, Brekken, Rolf A., Gerber, David E.
Published in Lung cancer (Amsterdam, Netherlands) (01.08.2023)
Published in Lung cancer (Amsterdam, Netherlands) (01.08.2023)
Get full text
Journal Article
AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial
Beumer, Niklas, Waizenegger, Jonas S., Heuser, Michael, Chromik, Jörg, Sutamtewagul, Grerk, Kapp-Schwoerer, Silke, Crugnola, Monica, Di Renzo, Nicola, Lemoli, Roberto M., Mattei, Daniele G., Fiedler, Walter, Alvarado-Valero, Yesid, Micklem, David, Nilsson, Linn H., Madeleine, Noelly, McCracken, Nigel, Oliva, Cristina, Gorcea-Carson, Claudia, Rieckmann, Lisa-Marie, Krause, Jenny, Gensch, Victoria, Ben Batalla, Isabel, Janning, Melanie, Gagliani, Nicola, Brors, Benedikt, Imbusch, Charles D., Gjertsen, Bjorn T., Loges, Sonja
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC
Blø, Magnus, Rayford, Austin, Madeleine, Noëlly, Gärtner, Fabian, Bohan, Dana, Ruggio, Natalie, Li, Huiyu, Girard, Luc, Brekken, Rolf, Minna, John, Ånerud, Marianne, Maury, Wendy, Gorcea-Carson, Claudia, Gausdal, Gro, Micklem, David R., McCracken, Nigel
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
Lahu, Gezim, Hünnemeyer, Andreas, Diletti, Edgar, Elmlinger, Martin, Ruth, Peter, Zech, Karl, McCracken, Nigel, Facius, Axel
Published in Clinical pharmacokinetics (01.09.2010)
Published in Clinical pharmacokinetics (01.09.2010)
Get full text
Journal Article
Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide
Lahu, Gezim, Huennemeyer, Andreas, von Richter, Oliver, Hermann, Robert, Herzog, Rolf, McCracken, Nigel, Zech, Karl
Published in Journal of clinical pharmacology (01.11.2008)
Published in Journal of clinical pharmacology (01.11.2008)
Get more information
Journal Article